JP2017526361A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526361A5
JP2017526361A5 JP2017511182A JP2017511182A JP2017526361A5 JP 2017526361 A5 JP2017526361 A5 JP 2017526361A5 JP 2017511182 A JP2017511182 A JP 2017511182A JP 2017511182 A JP2017511182 A JP 2017511182A JP 2017526361 A5 JP2017526361 A5 JP 2017526361A5
Authority
JP
Japan
Prior art keywords
signaling
domain
binding domain
car
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017511182A
Other languages
English (en)
Japanese (ja)
Other versions
JP6614619B2 (ja
JP2017526361A (ja
Filing date
Publication date
Priority claimed from GBGB1415347.2A external-priority patent/GB201415347D0/en
Application filed filed Critical
Publication of JP2017526361A publication Critical patent/JP2017526361A/ja
Publication of JP2017526361A5 publication Critical patent/JP2017526361A5/ja
Application granted granted Critical
Publication of JP6614619B2 publication Critical patent/JP6614619B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017511182A 2014-08-29 2015-08-28 シグナル伝達系 Active JP6614619B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1415347.2 2014-08-29
GBGB1415347.2A GB201415347D0 (en) 2014-08-29 2014-08-29 Signalling system
PCT/GB2015/052494 WO2016030691A1 (en) 2014-08-29 2015-08-28 Signalling system

Publications (3)

Publication Number Publication Date
JP2017526361A JP2017526361A (ja) 2017-09-14
JP2017526361A5 true JP2017526361A5 (cg-RX-API-DMAC7.html) 2018-08-09
JP6614619B2 JP6614619B2 (ja) 2019-12-04

Family

ID=51752358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511182A Active JP6614619B2 (ja) 2014-08-29 2015-08-28 シグナル伝達系

Country Status (18)

Country Link
US (2) US10654927B2 (cg-RX-API-DMAC7.html)
EP (2) EP3185875B1 (cg-RX-API-DMAC7.html)
JP (1) JP6614619B2 (cg-RX-API-DMAC7.html)
KR (1) KR102222615B1 (cg-RX-API-DMAC7.html)
CN (1) CN106573989B (cg-RX-API-DMAC7.html)
AU (1) AU2015308243B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017003906A2 (cg-RX-API-DMAC7.html)
CA (1) CA2955668A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000438A1 (cg-RX-API-DMAC7.html)
ES (1) ES2910008T3 (cg-RX-API-DMAC7.html)
GB (1) GB201415347D0 (cg-RX-API-DMAC7.html)
IL (1) IL250101B (cg-RX-API-DMAC7.html)
MX (1) MX376613B (cg-RX-API-DMAC7.html)
NZ (1) NZ728674A (cg-RX-API-DMAC7.html)
RU (1) RU2731638C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201700171VA (cg-RX-API-DMAC7.html)
WO (1) WO2016030691A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201700466B (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
CA2933707A1 (en) 2013-12-20 2015-06-25 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
EP3288570A4 (en) * 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
CN114634943A (zh) 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
GB201602571D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602563D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2018009923A1 (en) * 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
GB2564823B8 (en) 2016-10-07 2022-06-29 Tcr2 Therapeutics Inc Compositions and methods for TCR reprogramming using fusion proteins
JP2019535262A (ja) 2016-11-11 2019-12-12 オートラス リミテッド キメラ抗原受容体
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
GB201621891D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Transcription system
KR102624509B1 (ko) 2017-03-27 2024-01-12 싱가포르국립대학교 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
EP3600356A4 (en) 2017-03-27 2020-12-23 National University of Singapore TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY
CN110621694A (zh) * 2017-05-15 2019-12-27 奥托路斯有限公司 包含嵌合抗原受体(car)的细胞
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
GB201709508D0 (en) * 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
AU2018311345A1 (en) * 2017-08-02 2020-02-27 Autolus Limited Cells expressing a chimeric antigen receptor or engineered TCR and comprising a nucleotide sequence which is selectively expressed
CN107475276A (zh) * 2017-09-05 2017-12-15 深圳大学 嵌合抗原受体及其表达基因、四环素调节的嵌合抗原受体修饰的t细胞及其应用
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
GB201805918D0 (en) * 2018-04-10 2018-05-23 Autolus Ltd Cell
US20210113615A1 (en) 2018-04-13 2021-04-22 Ludwig Institute For Cancer Research Ltd. Heterodimeric inactivatable chimeric antigen receptors
GB201807693D0 (en) 2018-05-11 2018-06-27 Autolus Ltd Cell
EP3794034A1 (en) 2018-05-15 2021-03-24 Autolus Limited Chimeric antigen receptor
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
CN112601758A (zh) 2018-08-29 2021-04-02 新加坡国立大学 特异性刺激经基因修饰免疫细胞的存活和扩增的方法
WO2020051374A1 (en) * 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CA3113896A1 (en) 2018-09-27 2020-04-02 Autolus Limited Chimeric antigen receptor
GB201816839D0 (en) * 2018-10-16 2018-11-28 Glaxosmithkline Ip Dev Ltd Novel control switch
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
US20220145325A1 (en) 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
GB201906202D0 (en) 2019-05-02 2019-06-19 Autolus Ltd Cell
US20220257757A1 (en) 2019-07-16 2022-08-18 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
GB201913258D0 (en) 2019-09-13 2019-10-30 Autolus Ltd Antigen-binding domain
GB201919019D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
GB201919017D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Cell
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
WO2021205175A1 (en) 2020-04-09 2021-10-14 Autolus Limited Molecule
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
GB202017343D0 (en) 2020-11-02 2020-12-16 Autolus Ltd Cell
GB202104030D0 (en) 2021-03-23 2021-05-05 Autolus Ltd Signalling system
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
GB202219568D0 (en) 2022-12-22 2023-02-08 Autolus Ltd Chimeric antigen receptor
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6034696B2 (ja) * 2010-02-12 2016-11-30 オンコメッド ファーマシューティカルズ インコーポレイテッド ポリペプチド発現細胞の同定及び単離の方法
PL3300745T3 (pl) * 2013-02-15 2020-03-31 The Regents Of The University Of California Chimeryczny receptor antygenowy i sposoby jego zastosowania
SG11201508805UA (en) 2013-05-13 2015-11-27 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
EP3071221A1 (en) * 2013-11-21 2016-09-28 UCL Business Plc. Cell
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
US9791929B2 (en) * 2014-10-31 2017-10-17 Elwha Llc Tactile control system
KR102376244B1 (ko) * 2014-12-24 2022-03-21 오토러스 리미티드 세포
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
SG11201805792PA (en) * 2016-01-11 2018-08-30 Univ Leland Stanford Junior Chimeric proteins and methods of regulating gene expression
GB201602563D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602571D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201610515D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Cell

Similar Documents

Publication Publication Date Title
JP2017526361A5 (cg-RX-API-DMAC7.html)
Kamiya et al. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
RU2017105515A (ru) Сигнальная система
JP6909844B2 (ja) 細胞
JP7068459B2 (ja) Nyeso tcr
Zhao et al. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
Jamieson et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing
Dargel et al. T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice
JP2023518049A (ja) 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
Zhang et al. Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody
JP2016538855A5 (cg-RX-API-DMAC7.html)
JP2019530431A5 (cg-RX-API-DMAC7.html)
RU2016124278A (ru) Клетка
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
BR112021007626A2 (pt) Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
FI4050034T3 (fi) Cd3:een sitoutuvia vasta-aineita
KR20240063204A (ko) Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
JP2019535262A5 (cg-RX-API-DMAC7.html)
IL268620B2 (en) Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
JP2016520074A5 (cg-RX-API-DMAC7.html)
JP2021503006A5 (cg-RX-API-DMAC7.html)
JP2017513478A5 (cg-RX-API-DMAC7.html)
JP2019506841A5 (cg-RX-API-DMAC7.html)
JP2020512973A5 (cg-RX-API-DMAC7.html)
JP2019513394A5 (cg-RX-API-DMAC7.html)